Skip to search boxSkip to navigationSkip to main content

The safety of anidulafungin

*Corresponding author for this work
  • Wayne State University
    ,
  • Henry Ford Health System
Scholary Output:
Contribution to journal
Review article
Peer-review

Abstract

The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 751-758 (8 pages)

Journal (Volume, Issue Number)

Expert Opinion on Drug Safety (Volume 5, Issue 6)

Publication milestones

  • Published - 11/2006

Publication status

Published - 11/2006

ISSN

1474-0338

Publication IDs

  • Scopus: 33750553597
  • PubMed: 17044802

Publication metrics

Metrics

SciVal
FWCI
0.66
SciVal
Author count
1
SciVal
citations
20
SciVal
Paper percentile
73
Scopus
citations
Fractional count
1
Fractional count
1
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
20
Captures
13